



Isabelle Plo graduated with a Ph.D in Physiopathology in 2002 in hematology (University of Toulouse, France). She is now INSERM director of research and head of INSERM research hematology unit in Gustave Roussy (Villejuif, France). Her main interest is the study of myeloproliferative neoplasms (MPN) with three axes: decipher the signaling involved by driver mutations, identify germline predisposition and their mechanisms of action, characterize new selective treatments and their mechanism of action. Her major scientific contributions include the discovery of TET2 mutations and their involvement in the pathogenesis of MPNs, the identification of multiple germline predisposition factors and the characterization of the molecular mechanisms underlying mutant CALR activity contributing to the development of novel targeted therapeutic approaches.